Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 304Carcinoma, Non-Small-Cell Lung 182Ovarian Neoplasms 154Lung Neoplasms 92Esophageal Neoplasms 75Triple Negative Breast Neoplasms 71Stomach Neoplasms 71Fallopian Tube Neoplasms 68Squamous Cell Carcinoma of Head and Neck 51Esophageal Squamous Cell Carcinoma 50Neoplasm Metastasis 48Neoplasms 45Endometrial Neoplasms 42Head and Neck Neoplasms 41Carcinoma, Ovarian Epithelial 41Uterine Cervical Neoplasms 37Recurrence 26Carcinoma, Squamous Cell 23Adenocarcinoma Of Esophagus 22Urinary Bladder Neoplasms 19Melanoma 19Inflammatory Breast Neoplasms 19Prostatic Neoplasms 18Adenocarcinoma of Lung 17Carcinoma 15Breast Neoplasms, Male 15Unspecified Adult Solid Tumor, Protocol Specific 14Testicular Neoplasms 13Small Cell Lung Carcinoma 12Peritoneal Neoplasms 12

Interventions

Chemoradiotherapy 2Radiation 1Paclitaxel 1Granulocyte-Macrophage Colony-Stimulating Factor 1Colony-Stimulating Factors 1Cetuximab 1Carboplatin 1Adjuvants, Immunologic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Resectable Esophageal Cancer × Paclitaxel × Clear all
NCT03490292 2024-07-26

Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer

University of Wisconsin, Madison

Phase 1/2 Completed
22 enrolled 17 charts
Gastrointestinal

Resectable Esophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡